S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations (2013/10/21)|
|Clovis Oncology Announces First Patient Treated with Hydrobromide Salt Tablet Formulation of CO-1686 in its Ongoing Phase I/II Clinical Study (2013/8/28)|
|Clovis Oncology Announces Second Quarter 2013 Operating Results (2013/8/1)|
|Clovis Oncology Announces Lung Cancer Diagnostic Collaboration with QIAGEN (2013/10/21)|
|Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference ()|
|Clovis Oncology Acquires EOS (Ethical Oncology Science) S.p.A. to Gain Rights to Lucitanib, a Unique Dual-Selective Phase II FGFR/VEGFR Inhibitor (2013/11/19)|
|Clovis Oncology’s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study Results ()|
|Clovis Oncology Announces CO-1686 Clinical Data Accepted as Oral Presentation at 2014 European Lung Cancer Conference ()|
|Clovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1 Study Results in Patients with Non-small Cell Lung Cancer (NSCLC) (2014/3/27)|
|Clovis Oncology, seen as 'next ICPT,' jumps 5% ()|
Click above to view more mutual fund data and stats for clvs - Clovis Oncology Inc.